Search hospitals > Ohio > Toledo

University of Toledo

Claim this profile
Toledo, Ohio 43614
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Non-Small Cell Lung Cancer
207 reported clinical trials
8 medical researchers
Photo of University of Toledo in ToledoPhoto of University of Toledo in ToledoPhoto of University of Toledo in Toledo

Summary

University of Toledo is a medical facility located in Toledo, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. University of Toledo is involved with conducting 207 clinical trials across 354 conditions. There are 8 research doctors associated with this hospital, such as Roland Skeel, MD, Mouhammad Jumaa, MD, Firas G. Petros, and Imran Ali.

Area of expertise

1Cancer
Global Leader
University of Toledo has run 51 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
University of Toledo has run 24 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
PR positive

Top PIs

Clinical Trials running at University of Toledo

Non-Small Cell Lung Cancer
Lung Cancer
Prostate Cancer
Cancer
Bladder Cancer
Pancreatic Cancer
Renal Cell Carcinoma
Syndrome
Lennox Gastaut Syndrome
ALK Gene Rearrangement
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Genetic Testing

for Early-Stage Lung Cancer

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Toledo?
University of Toledo is a medical facility located in Toledo, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. University of Toledo is involved with conducting 207 clinical trials across 354 conditions. There are 8 research doctors associated with this hospital, such as Roland Skeel, MD, Mouhammad Jumaa, MD, Firas G. Petros, and Imran Ali.